TLDR:
- Metsera, a NYC-based clinical-stage biopharmaceutical company, raised $290M in funding.
- The round was led by ARCH Venture Partners with participation from other healthcare investors.
Metsera, a clinical-stage biopharmaceutical company, has launched with $290M in funding. The funding round was led by ARCH Venture Partners and included participation from other healthcare investors such as F-Prime Capital, GV, Mubadala Capital, Newpath Partners, and SoftBank Vision Fund 2. The company plans to use the funds to expand operations and its research and development sector.
Metsera is focused on developing next-generation medicines for obesity and metabolic diseases. The company has a broad portfolio of oral and injectable therapies targeting multiple therapeutic targets. These include a GLP-1 portfolio with an injectable GLP-1 receptor agonist in Phase 1 clinical trials, a dual amylin/calcitonin receptor agonist, and a unimolecular GGG engineered for class-leading duration of effect. The company also has an oral peptide delivery platform with two IND-ready candidates and multiple first-in-class oral follow-on candidates, as well as other early-stage programs and delivery modalities.
Overall, Metsera’s focus on developing innovative therapies for obesity and metabolic diseases, along with its extensive funding, positions the company well to make significant advancements in the field of biopharmaceuticals.
